股票代码RMD,瑞思迈医疗公司今日股价盘中大涨8.63%,引起市场广泛关注。公司此前公布的2024财年第一季度业绩显示,营收同比增长11%至12.2亿美元,调整后每股收益2.2美元,均超出分析师此前预期。
该佳绩主要得益于公司旗下用于治疗睡眠呼吸暂停的设备及相关面罩产品组合需求强劲。作为该领域的领军企业,瑞思迈凭借核心产品的出色表现,展现了巨大的市场潜力,增强了投资者对其长期发展前景的信心。分析师预计,未来即便市场环境发生变化,瑞思迈在无创睡眠呼吸暂停治疗领域的产品销量依然将保持旺盛态势。
受超预期业绩和光明长期前景的提振,市场最新预期瑞思迈2025财年每股收益将达到9.25美元,营收将达到50.85亿美元。分析师也上调了对该股的目标价,中位数为262.39美元,较此前上涨近5%。这进一步反映出市场对瑞思迈未来发展的乐观预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.